Log in

Relevant bibliographies by topics / CD47 / Journal articles

To see the other types of publications on this topic, follow the link: CD47.

Journal articles on the topic 'CD47'

Author: Grafiati

Published: 4 June 2021

Last updated: 21 December 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'CD47.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Nguyen, Oanh Thi-Kieu, Anh Nguyen Tu Bui, Ngoc Bich Vu, and Phuc Van Pham. "ID: 1077 Overexpress of CD47 does not alter stemness of MCF-7 breast cancer cells." Biomedical Research and Therapy 4, S (2017): 163. http://dx.doi.org/10.15419/bmrat.v4is.351.

Full text

Abstract:

Background: CD47 is a transmembrane glycoprotein expressed on all cells in the body and particularly overexpressed on cancer cells and cancer stem cells of both hematologic and solid malignancies. In the immune system, CD47 acts as a "don't eat me" signal, inhibiting phagocytosis by macrophages by interaction with signal regulatory protein α (SIRPα). In cancer, CD47 promotes tumor invasion and metastasis. This study aimed to evaluate the stemness of breast cancer cells when CD47 is overexpressed. Methods: MCF-7 breast cancer cells were transfected with plasmid pcDNA3.4-CD47 containing th

APA, Harvard, Vancouver, ISO, and other styles

2

Liu, Xiaodan, Hong Zhou, Shihao Lu, et al. "Abstract 2715: Preclinical characterization of SM2248: A dual-action bispecific antibody enhancing immunotherapy for solid tumors." Cancer Research 84, no. 6_Supplement (2024): 2715. http://dx.doi.org/10.1158/1538-7445.am2024-2715.

Full text

Abstract:

Abstract Background: Innate immune cells, such as macrophages and myeloid-derived suppressor cells (MDSCs), dominate the immune landscape within "cold" solid tumors, which typically exhibit poor responses to immune checkpoint inhibitors (ICIs). The dearth of tumor-infiltrating T cells and the prevailing immunosuppressive microenvironment contribute to this ineffectiveness. To bolster immunotherapy against such tumors, we developed SM2248, a bispecific VHH antibody. SM2248 simultaneously obstructs the CD47-SIRPα phagocytosis checkpoint pathway and conditionally activates CD40 on tumor-infiltrat

APA, Harvard, Vancouver, ISO, and other styles

3

Majeti, Ravindra, Mark P. Chao, Ash A. Alizadeh, Wendy W. Pang, and Irving L. Weissman. "CD47 Is An Independent Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells." Blood 112, no. 11 (2008): 766. http://dx.doi.org/10.1182/blood.v112.11.766.766.

Full text

Abstract:

Abstract A growing body of evidence has added to our fundamental knowledge by demonstrating that human acute myelogenous leukemia (AML) is organized as a cellular hierarchy initiated and maintained by rare self-renewing leukemia stem cells (LSC). One implication of this cancer stem cell model is that in order to eradicate the leukemia and cure the patient, therapies must target and eliminate the leukemia stem cells. For the development of such LSC-targeted therapies, it is necessary to identify molecules that are preferentially expressed in LSC compared to their normal counterparts and that ar

APA, Harvard, Vancouver, ISO, and other styles

4

Pettersen, Rolf D., Kjetil Hestdal, Mette Kløvstad Olafsen, Sverre O. Lie, and Frederik P. Lindberg. "CD47 Signals T Cell Death." Journal of Immunology 162, no. 12 (1999): 7031–40. http://dx.doi.org/10.4049/jimmunol.162.12.7031.

Full text

Abstract:

Abstract Activation-induced death of T cells regulates immune responses and is considered to involve apoptosis induced by ligation of Fas and TNF receptors. The role of other receptors in signaling T cell death is less clear. In this study we demonstrate that activation of specific epitopes on the Ig variable domain of CD47 rapidly induces apoptosis of T cells. A new mAb, Ad22, to this site induces apoptosis of Jurkat cells and CD3ε-stimulated PBMC, as determined by morphological changes, phosphatidylserine exposure on the cell surface, uptake of propidium iodide, and true counts by flow cytom

APA, Harvard, Vancouver, ISO, and other styles

5

Stirling, Elizabeth, Adam Wilson, Katherine Cook, Alexandra Thomas, Pierre Triozzi, and David Soto-Pantoja. "616 CD47 blockade modulates immunosuppressive checkpoint molecules and cellular metabolism to sensitize triple-negative breast cancer tumors to immune checkpoint blockade therapy." Journal for ImmunoTherapy of Cancer 9, Suppl 2 (2021): A646. http://dx.doi.org/10.1136/jitc-2021-sitc2021.616.

Full text

Abstract:

BackgroundTriple-negative breast cancer(TNBC) lacks druggable targets and has high metastatic incidence. Immune checkpoint blockades (ICB) are FDA approved for TNBC treatment, but therapeutic response and biomarkers are limited. CD47 is an integral membrane protein overexpressed on cancer cells that alters anti-tumor immunosurveillance, resulting in tumor progression. CD47 is involved in metabolic reprogramming but whether CD47 is a marker of progression and its role in ICB response for TNBC remains unknown.MethodsHuman TNBC biopsies were subjected to immunohistochemical analysis to determine

APA, Harvard, Vancouver, ISO, and other styles

6

Yao, Molly, Jalicia Sturdivant, Aren Ebrahimi, Samayita Ganguly, and Tamer Elbayoumi. "Novel Pharmaceutical Strategy for Selective Abrogation of TSP1-Induced Vascular Dysfunction by Decoy Recombinant CD47 Soluble Receptor in Prophylaxis and Treatment Models." Biomedicines 9, no. 6 (2021): 642. http://dx.doi.org/10.3390/biomedicines9060642.

Full text

Abstract:

Elevated thrombospondin 1 (TSP1) is a prevalent factor, via cognate receptor CD47, in the pathogenesis of cardiovascular conditions, including ischemia-reperfusion injury (IRI) and pulmonary arterial hypertension (PAH). Moreover, TSP1/CD47 interaction has been found to be associated with platelet hyperaggregability and impaired nitric oxide response, exacerbating progression in IRI and PAH. Pathological TSP1 in circulation arises as a target of our novel therapeutic approach. Our “proof-of-concept” pharmacological strategy relies on recombinant human CD47 peptide (rh-CD47p) as a decoy receptor

APA, Harvard, Vancouver, ISO, and other styles

7

Schuurhuis, Gerrit J., Rolf Wouters, Angèle Kelder, et al. "Specificity of Markers of Leukemia Initiating Cells with a New Multiparameter Flow Cytometry Based Appraoch; Impact for Prognostic and Therapeutic Applications." Blood 116, no. 21 (2010): 1834. http://dx.doi.org/10.1182/blood.v116.21.1834.1834.

Full text

Abstract:

Abstract Abstract 1834 Leukemia stem cells (LSC) are proposed to underly relapse of AML. In order to develop methods to specifically detect LSCs and to design LSC specific therapies, discrimination between LSC and normal hematopoietic stem cells (HSC) is a prerequisite. HSC and LSC may be either CD34-positive (CD34+CD38-) or CD34-negative. The latter may be contained in stem cell compartments defined by functional parameters: Hoechst 33342 efflux (side population, SP) and ALDH activity. To discriminate between LSCs and HSCs aberrant cell surface markers have been described. Additional flowcyto

APA, Harvard, Vancouver, ISO, and other styles

8

Murphy, Philip, Edel Mullen, Stephen Bergin, et al. "Red Blood Cells from COVID-19 Patients Show Evidence of Increased Oxidative Stress and Increased Lactate Influx." Blood 138, Supplement 1 (2021): 928. http://dx.doi.org/10.1182/blood-2021-146305.

Full text

Abstract:

Abstract Red Blood Cells from COVID-19 Patients Show Evidence of Increased Oxidative Stress and Increased Lactate Influx Corona Disease 19 (COVID-19) is caused by SARS-CoV-2, a novel, highly infectious, single stranded RNA virus. In severe cases, excess oxidative stress produced by a 'cytokine storm' may generate excess reactive oxygen species (ROS) and lead to tissue damage in the lungs and elsewhere. As the potential role of RBCs in the pathophysiology of COVID-19 remains controversial (1), we investigated for evidence of increased oxidative stress and increased thrombotic tendency in RBCs f

APA, Harvard, Vancouver, ISO, and other styles

9

Olsson, Mattias, Pierre Bruhns, William A. Frazier, Jeffrey V. Ravetch, and Per-Arne Oldenborg. "Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia." Blood 105, no. 9 (2005): 3577–82. http://dx.doi.org/10.1182/blood-2004-08-2980.

Full text

Abstract:

Abstract Interaction between target cell CD47 and the inhibitory macrophage receptor signal regulatory protein α (SIRPα) counteracts macrophage phagocytosis of CD47-expressing host cells. As platelets also express CD47, we asked whether inhibitory CD47/SIRPα signaling regulates normal platelet turnover and clearance of platelets in immune thrombocytopenic purpura (ITP). CD47-/- mice had a mild spontaneous thrombocytopenia, which was not due to a decreased platelet half-life as a result of increased expression of P-selectin, CD61, or phosphatidylserine. In contrast, CD47-/- platelets were rapid

APA, Harvard, Vancouver, ISO, and other styles

10

Blazar, Bruce R., Frederik P. Lindberg, Elizabeth Ingulli, et al. "Cd47 (Integrin-Associated Protein) Engagement of Dendritic Cell and Macrophage Counterreceptors Is Required to Prevent the Clearance of Donor Lymphohematopoietic Cells." Journal of Experimental Medicine 194, no. 4 (2001): 541–50. http://dx.doi.org/10.1084/jem.194.4.541.

Full text

Abstract:

Integrin-associated protein (CD47) is a broadly expressed protein that costimulates T cells, facilitates leukocyte migration, and inhibits macrophage scavenger function. To determine the role of CD47 in regulating alloresponses, CD47+/+ or CD47−/− T cells were infused into irradiated or nonconditioned major histocompatibility complex disparate recipients. Graft-versus-host disease lethality was markedly reduced with CD47−/− T cells. Donor CD47−/− T cells failed to engraft in immunodeficient allogeneic recipients. CD47−/− marrow was unable to reconstitute heavily irradiated allogeneic or congen

APA, Harvard, Vancouver, ISO, and other styles

11

Zhang, Richard, and Haishan Lin. "Abstract 5204: Optimization of novel anti-human CD47 antibody prodrugs as cancer therapeutics with low on-target toxicity." Cancer Research 82, no. 12_Supplement (2022): 5204. http://dx.doi.org/10.1158/1538-7445.am2022-5204.

Full text

Abstract:

Abstract CD47 is a well-studied target for cancer immunotherapy. Blocking of CD47 binding to its receptor, SIRPα, on macrophages leads to inhibition of macrophage activation and phagocytosis. Several monoclonal anti-CD47 antibodies are currently in various stages of clinical development. However, since CD47 is also expressed on normal cells such as red blood cells and platelets, anti-CD47 antibodies also caused on-target side effects during clinical evaluations, such as anemia and red blood cell hemagglutination. To minimize the on-target side effects of anti-CD47 antibodies, we have generated

APA, Harvard, Vancouver, ISO, and other styles

12

Jajosky, Ryan, Connie Arthur, Jerry Allen, et al. "CD47 Regulates Red Blood Cell Alloimmunization in Mice." Blood 134, Supplement_1 (2019): 100. http://dx.doi.org/10.1182/blood-2019-131598.

Full text

Abstract:

Background: Exposure to red blood cell (RBC) alloantigens during pregnancy or transfusion can lead to the development of alloantibodies and result in transfusion-related complications, including hemolytic transfusion reactions and hemolytic disease of the fetus and newborn. However, the factors that regulate RBC alloimmunization remain incompletely understood. Several studies suggest that alterations in factors that regulate RBC clearance may impact RBC uptake and antigen presentation, directly influencing the likelihood of RBC alloimmunization. To test this, we directly examined the potential

APA, Harvard, Vancouver, ISO, and other styles

13

Liang, Juan, Cunxiang Ju, Song Li та ін. "Abstract 607: Humanized mice model for efficacy and toxicity evaluation of drugs targeting CD47-SIRPα-PD1-PD-L1 axes". Cancer Research 82, № 12_Supplement (2022): 607. http://dx.doi.org/10.1158/1538-7445.am2022-607.

Full text

Abstract:

Abstract CD47 is widely expressed on the surface of cells. CD47 interacts with inhibitory receptor signaling protein alpha (SIRPα) to mediate a series of activities such as apoptosis, proliferation, and immune response. Tumor cells can escape the immune surveillance of macrophages through the CD47-SIRPa signaling pathway. Blocking CD47-SIRPα interactions has been shown to promote the destruction of cancer cells by phagocytes. Furthermore, there is growing evidence that targeting of the CD47-SIRPα axis may also promote antigen-presenting cell function. These identify the CD47-SIRPα axis as a pr

APA, Harvard, Vancouver, ISO, and other styles

14

Wang, Xinhua, Oi Kwan Wong, Leonard Post, and Xiaocheng Chen. "Abstract 3430: CD47 x ICAM-1 bispecific antibody represents a novel approach for treating ICAM-1 overexpressing tumors." Cancer Research 82, no. 12_Supplement (2022): 3430. http://dx.doi.org/10.1158/1538-7445.am2022-3430.

Full text

Abstract:

Abstract CD47/SIRPa axis is an important checkpoint of innate immune system, CD47 interacts with its ligand signal regulatory protein-alpha (SIRPa) on myeloid cells, conveys a “don’t eat me” signal and blocks macrophage mediated phagocytosis. Tumor cells, which express high level of CD47, exploit this mechanism to evade from immune surveillance. CD47 is considered a prominent target for cancer treatment. However, the wide expression of CD47 on normal cells could cause antigen sink and lead to safety issues, such as anemia and thrombocytopenia. ICAM-1 is constitutively present at low levels on

APA, Harvard, Vancouver, ISO, and other styles

15

Galeana Figueroa, Maday, Kishan Nyati, Tarang Sharma, et al. "CD47-CD138 Bispecific Antibody Exhibits Selective Targeting of Multiple Myeloma." Blood 144, Supplement 1 (2024): 4812. https://doi.org/10.1182/blood-2024-208382.

Full text

Abstract:

CD47 is a “do not eat me signal” that is overexpressed on malignant tumors including multiple myeloma (MM). CD47 on tumor cells interacts with SIRP-α on macrophages and inhibits its phagocytosis enabling tumor progression. Clinical studies with antibodies blocking CD47-SIRP-α interaction to promote tumor phagocytosis have shown varying success. CD47 is widely expressed on normal tissues thus, monoclonal antibodies binding to these can lead to loss of treatment efficacy due to “sink effect” and to off-tumor on-target toxicity. In addition, when used as an adjuvant, CD47 antibody had a deleterio

APA, Harvard, Vancouver, ISO, and other styles

16

Cham, Lamin B., Tom Adomati, Fanghui Li, Murtaza Ali, and Karl S. Lang. "CD47 as a Potential Target to Therapy for Infectious Diseases." Antibodies 9, no. 3 (2020): 44. http://dx.doi.org/10.3390/antib9030044.

Full text

Abstract:

The integrin associated protein (CD47) is a widely and moderately expressed glycoprotein in all healthy cells. Cancer cells are known to induce increased CD47 expression. Similar to cancer cells, all immune cells can upregulate their CD47 surface expression during infection. The CD47-SIRPa interaction induces an inhibitory effect on macrophages and dendritic cells (dendritic cells) while CD47-thrombospondin-signaling inhibits T cells. Therefore, the disruption of the CD47 interaction can mediate several biologic functions. Upon the blockade and knockout of CD47 reveals an immunosuppressive eff

APA, Harvard, Vancouver, ISO, and other styles

17

Ko, Yunmi, Seog-Yun Park, Jong Woong Park, June Hyuk Kim, Hyun Guy Kang, and Jun Ah Lee. "CD47 in Osteosarcoma: Correlation with Metastasis and Macrophage-Mediated Phagocytosis." Cells 13, no. 22 (2024): 1862. http://dx.doi.org/10.3390/cells13221862.

Full text

Abstract:

CD47 is expressed on cell surfaces and acts as a “don’t eat me” signal by interacting with signal-regulatory protein-α on the macrophage surface. Some cancer cells express CD47 protein and can evade macrophage phagocytosis. Herein, we evaluated the feasibility of targeting CD47 for osteosarcoma by analyzing its expression patterns, clinicopathological correlations, and immunotherapeutic potential. We performed a retrospective analysis on 24 biopsy samples from patients with osteosarcoma to investigate correlations between CD47 protein positivity and clinicopathological characteristics. CD47 pr

APA, Harvard, Vancouver, ISO, and other styles

18

Park, Jin Kyun, Ye Ji Lee, Ji Soo Park, Eun Bong Lee, and Yeong Wook Song. "CD47 Potentiates Inflammatory Response in Systemic Lupus Erythematosus." Cells 10, no. 5 (2021): 1151. http://dx.doi.org/10.3390/cells10051151.

Full text

Abstract:

Background: To investigate the role of CD47 in inflammatory responses in systemic lupus erythematosus (SLE). Methods: Expression of CD47 and signal regulatory protein alpha (SIRPα) by peripheral blood mononuclear cells (PBMCs) and changes in CD47 expression after exposure to SLE serum, healthy control (HC) serum, recombinant interferon (IFN)-α, or tumor necrosis factor (TNF)-α were examined. Human monocytes and THP1 cells were incubated with lipopolysaccharide (LPS), an anti-CD47 antibody, or both. TNF-α production was examined. Sera from SLE patients and HCs were screened to detect autoantibo

APA, Harvard, Vancouver, ISO, and other styles

19

Persaud, Stephen P., Aditya R. Yelamali, Julie K. Ritchey та John F. DiPersio. "Anti-CD117 Plus Anti-Sirpα or Fc-Silenced Anti-CD47 Enables Hematopoietic Stem Cell Depletion and Syngeneic Engraftment without Development of Severe Anemia". Blood 144, Supplement 1 (2024): 2019. https://doi.org/10.1182/blood-2024-200305.

Full text

Abstract:

INTRODUCTION: In preparation for hematopoietic stem cell transplantation (HSCT), recipients are conditioned with chemotherapy and irradiation to enable donor hematopoietic stem cell (HSC) engraftment. The acute and chronic toxicities caused by these conditioning regimens negatively impact quality of life, life expectancy, and fertility, and may prevent unfit patients from undergoing HSCT at all. Antibody-drug conjugates (ADC) have been shown to enable HSCT within and across immunological barriers in preclinical models with fewer adverse effects (Persaud et al (2021); J Clin Invest), but even A

APA, Harvard, Vancouver, ISO, and other styles

20

Zhuang, Wenzhuo, and Bingzong Li. "Suppression of Extracellular Vesicle CD47 Induces Systemic Anti-DLBCL Immunity." Blood 138, Supplement 1 (2021): 716. http://dx.doi.org/10.1182/blood-2021-152451.

Full text

Abstract:

Abstract Purpose: Tumor cells evade the immune surveillance by up-regulating surface expression of CD47, which interacts with SIRPa on macrophages to elicit the immune checkpoint response. Anti-CD47 antibody (IBI188) has shown promise in treating tumors, including Diffuse large B cell lymphoma (DLBCL). The objective response rate among DLBCL was 73% (ClinicalTrials.gov number, NCT02953509.). The basis of differential therapeutic success between patients remains unknown. Extracellular vesicles (EVs) carry bioactive molecules that influence the immune system. CD47 has be found on surface of EVs.

APA, Harvard, Vancouver, ISO, and other styles

21

Wang, Hui, Jon VerHalen, Maria Lucia Madariaga, et al. "Attenuation of phagocytosis of xenogeneic cells by manipulating CD47." Blood 109, no. 2 (2006): 836–42. http://dx.doi.org/10.1182/blood-2006-04-019794.

Full text

Abstract:

Abstract Signal regulatory protein α (SIRPα) is a critical immune inhibitory receptor on macrophages, and its interaction with CD47, a ligand for SIRPα, prevents autologous phagocytosis. We hypothesized that interspecies incompatibility of CD47 may contribute to the rejection of xenogeneic cells by macrophages. Here, we show that pig CD47 does not interact with mouse SIPRα. Similar to CD47−/− mouse cells, porcine red blood cells (RBCs) failed to induce SIRPα tyrosine phosphorylation in mouse macrophages. Blocking SIRPα with antimouse SIRPα mAb (P84) significantly enhanced the phagocytosis of C

APA, Harvard, Vancouver, ISO, and other styles

22

Ren, Shuai, Xiangxiang Zhou, Shunfeng Hu, et al. "Berberine Mediated CD47-Blocking As a Potential Immunotherapy in Diffuse Large B-Cell Lymphoma." Blood 136, Supplement 1 (2020): 10–12. http://dx.doi.org/10.1182/blood-2020-139508.

Full text

Abstract:

Keywords diffuse large B-cell lymphoma; CD47; berberine; immunotherapy; macrophage Introduction Cluster of differentiation 47 (CD47) is a tetraspanin that expresses widely in human tissue and overexpresses in several malignance cells. The interaction between CD47 overexpressing on tumor cells and signal regulatory protein alpha (SIRP-α) on macrophages triggers an inhibitory signal cascade that suppresses the phagocytosis function. Berberine is a quaternary amine isoquinoline alkaloid which is traditionally used in intestinal infection and found to have anti-tumor activities in several tumors.

APA, Harvard, Vancouver, ISO, and other styles

23

Suh, Jin Kyung, Jun Ah Lee, Yunmi Ko, Meerim Park, and Hyeon Jin Park. "Macrophage Immune Checkpoint for Immunotherapy of Osteosarcoma." Blood 142, Supplement 1 (2023): 5353. http://dx.doi.org/10.1182/blood-2023-191342.

Full text

Abstract:

Purpose: Macrophages account for the majority of immune cells infiltrated in sarcoma tissues. CD47 is a “don't eat me” signal expressed on the cell surface. We tested a feasibility of CD47, a macrophage immune checkpoint, for immunotherapy of osteosarcoma. Methods: Twenty-four biopsy samples of osteosarcoma patients younger than 20 years were retrospectively analyzed for CD47 protein expression by immunohistochemistry. Relationships between CD47 expression and clinicopathologic characteristics were evaluated. Two osteosarcoma cell lines, KHOS/NP and MG63, were analyzed for CD47 expression by w

APA, Harvard, Vancouver, ISO, and other styles

24

Podolnikova, Nataly, Arnat Balabiyev та Tatiana P. Ugarova. "Association of CD47 with Integrin Mac-1 (αMβ2, CD11b/CD18) Regulates Macrophage Responses". Blood 132, Supplement 1 (2018): 1109. http://dx.doi.org/10.1182/blood-2018-99-119123.

Full text

Abstract:

Abstract CD47 is a cell surface receptor, which is expressed by virtually all cells in the body, including immune cells. CD47 has originally been identified as an integrin-associated protein (IAP) and shown to associate with several integrins that belong to the β1 and β3 subfamilies. In addition, association of CD47 with a member of the β2 subfamily, integrin αLβ2, has also been reported. In neutrophils, CD47 mediates a number of integrin αvβ3-dependent functions, including adhesion, migration and phagocytosis. Surprisingly, the association of CD47 with integrin αMβ2 (Mac-1, CD11b/CD18, CR3),

APA, Harvard, Vancouver, ISO, and other styles

25

Beckett, Alex N., Peter Chockley, Shondra M. Pruett-Miller, et al. "CD47 expression is critical for CAR T-cell survival in vivo." Journal for ImmunoTherapy of Cancer 11, no. 3 (2023): e005857. http://dx.doi.org/10.1136/jitc-2022-005857.

Full text

Abstract:

BackgroundCD47 is an attractive immunotherapeutic target because it is highly expressed on multiple solid tumors. However, CD47 is also expressed on T cells. Limited studies have evaluated CD47-chimeric antigen receptor (CAR) T cells, and the role of CD47 in CAR T-cell function remains largely unknown.MethodsHere, we describe the development of CD47-CAR T cells derived from a high affinity signal regulatory protein α variant CV1, which binds CD47. CV1-CAR T cells were generated from human peripheral blood mononuclear cells and evaluated in vitro and in vivo. The role of CD47 in CAR T-cell func

APA, Harvard, Vancouver, ISO, and other styles

26

Yang, Mei, Chunfan Jiang, Lin Li, Hui Xing, and Li Hong. "Expression of CD47 in Endometrial Cancer and Its Clinicopathological Significance." Journal of Oncology 2022 (March 4, 2022): 1–10. http://dx.doi.org/10.1155/2022/7188972.

Full text

Abstract:

Purpose. To study the prognostic value of CD47 in endometrial carcinoma (EC) and its correlation with clinicopathological variables. Methods. Next-generation sequencing data from The Cancer Genome Atlas was analyzed with the Kaplan–Meier curve, Cox’s regression model, and ROC curve. A cohort of 544 specimens, including 344 cases of endometrial cancer, 92 cases of endometrial hyperplasia (EH), and 118 cases of normal endometrium (NE), were evaluated with immunohistochemistry and analyzed with statistical methods. Results. For TCGA data, CD47 expression in EC was considerably greater than in NE

APA, Harvard, Vancouver, ISO, and other styles

27

wen, Chiao Kai, Jeanne Elia, Lorraine Loter, et al. "Immune cell phenotype and cytokine secretion in mouse breast cancer responding to anti-CD47 antibody treatment." Journal of Immunology 202, no. 1_Supplement (2019): 194.38. http://dx.doi.org/10.4049/jimmunol.202.supp.194.38.

Full text

Abstract:

Abstract Anti-CD47 antibodies have been shown to inhibit the progression of several types of cancer by blocking the “don’t eat me” signals to macrophage through CD47/SIRPα interaction, causing phagocytosis of tumor cell. However, mechanistic details in the response of the cancer cells still remain to be explored. In this study, we investigated different cytokine levels in 4T1 mammary carcinoma induced mouse breast cancer model with or without anti-mouse CD47 monoclonal antibody treatment. The data showed that this cancer model presented significantly higher percentages of CD11b+, CD43+, CD80+,

APA, Harvard, Vancouver, ISO, and other styles

28

Arai, Hiroyuki, Nishant Gandhi, Francesca Battaglin, et al. "The role of gene expression of CD47 in colorectal cancer (CRC)." Journal of Clinical Oncology 41, no. 4_suppl (2023): 240. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.240.

Full text

Abstract:

240 Background: CD47 belongs to the immunoglobulin superfamily and is overexpressed in many tumor types. CD47 plays an important role in suppressing phagocytosis through binding to transmembrane protein SIRP-alpha on macrophages. Targeting CD47 is a novel strategy for cancer immunotherapy and is being evaluated in ongoing clinical trials. However, molecular characteristics of CD47-overexpressed colorectal cancer (CRC) are largely unknown. Methods: We retrospectively reviewed CRC patient samples (n = 14786) submitted to a commercial CLIA-certified laboratory (Caris Life Sciences, Phoenix AZ). N

APA, Harvard, Vancouver, ISO, and other styles

29

Wang, Qianqian, Chunxaing Feng, Yuchun Chen, et al. "Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer." Journal of Immunology Research 2023 (September 9, 2023): 1–12. http://dx.doi.org/10.1155/2023/2473075.

Full text

Abstract:

Background. CD47 has high levels of expression in malignant cancer cells, which binds to SIRP-α to release the “don’t eat me” signal and prevents mononuclear macrophages from phagocytosing the cells. Resistance to drugs and metastases are potential barriers for prostate cancer endocrine therapy. Although immunotherapy for tumors has developed rapidly in the last few decades, its effectiveness in treating prostate cancer is unsatisfactory. Prostate cancer has a high-expression level of CD47. Therefore, a novel approach for potential immunotherapy may be provided by investigating the relationshi

APA, Harvard, Vancouver, ISO, and other styles

30

Miyashita, Motoaki, Hiroshi Ohnishi, Hideki Okazawa, et al. "Promotion of Neurite and Filopodium Formation by CD47: Roles of Integrins, Rac, and Cdc42." Molecular Biology of the Cell 15, no. 8 (2004): 3950–63. http://dx.doi.org/10.1091/mbc.e04-01-0019.

Full text

Abstract:

Axon extension during development is guided by many factors, but the signaling mechanisms responsible for its regulation remain largely unknown. We have now investigated the role of the transmembrane protein CD47 in this process in N1E-115 neuroblastoma cells. Forced expression of CD47 induced the formation of neurites and filopodia. Furthermore, an Fc fusion protein containing the extracellular region of the CD47 ligand SHPS-1 induced filopodium formation, and this effect was enhanced by CD47 overexpression. SHPS-1–Fc also promoted neurite and filopodium formation triggered by serum deprivati

APA, Harvard, Vancouver, ISO, and other styles

31

Mordue, Kathryn E., Timothy J. Satchwell, and Ashley M. Toye. "CD47 Is Dependent on the Actin Cytoskeleton for Its Membrane Stability Prior to Protein 4.2 Expression during Early Erythroblast Differentiation." Blood 124, no. 21 (2014): 2665. http://dx.doi.org/10.1182/blood.v124.21.2665.2665.

Full text

Abstract:

Abstract CD47 is a ubiquitously expressed ‘Marker of Self’ that protects cells from phagocytosis, through recognition by SIRPα on macrophages (Oldenborg et al Science 2000). CD47 was originally isolated on ovarian tumour cells (Poels et al J Natl Cancer Inst 1986) and has subsequently been detected on leukemic stem cells, where increased CD47 levels ensure immune evasion (Jaiswal et al Cell 2009). CD47 is also a ‘Marker of Self’ on red cells, but is reduced at the cell surface in certain patients with Hereditary Spherocytosis. In red cells, ~60% of CD47 is connected to the cytoskeleton (Dahl e

APA, Harvard, Vancouver, ISO, and other styles

32

Wang, Xinhua, Oi Kwan Wong, Lei Shi, Qi Fei, Leonard Post, and Xiaocheng Chen. "274 CD47 x EpCAM bispecific antibody represents a novel approach for treating EpCAM overexpressing solid tumors." Journal for ImmunoTherapy of Cancer 9, Suppl 2 (2021): A297. http://dx.doi.org/10.1136/jitc-2021-sitc2021.274.

Full text

Abstract:

BackgroundCD47 conveys a ”don’t eat me” signal through the interaction with its ligand signal regulatory protein-alpha (SIRPa) on myeloid cells and blocks macrophage mediated phagocytosis. Tumor cells, which express high level of CD47, exploit this mechanism to evade from immune surveillance. CD47/SIRPa axis is an important checkpoint of innate immune system and CD47 is considered a prominent target for cancer treatment.1 However, the wide expression of CD47 on normal cells could cause antigen sink and lead to safety issues, such as anemia and thrombocytopenia. EpCAM is highly expressed in man

APA, Harvard, Vancouver, ISO, and other styles

33

Lau, Asa P. Y., and Kelsie L. Thu. "Abstract B007: Upregulation of PD-L1 as a mechanism of resistance to CD47 inhibition in non-small cell lung cancer." Cancer Immunology Research 12, no. 10_Supplement (2024): B007. http://dx.doi.org/10.1158/2326-6074.tumimm24-b007.

Full text

Abstract:

Abstract Introduction: Evasion of the immune system is a hallmark of cancer and understanding immune escape mechanisms has led to the development of immunotherapies to boost anti-tumor immunity. CD47 is an immunosuppressive protein that transduces a “don’t eat me” signal when bound to the SIRPα receptor on antigen presenting cells (APCs). Cancer cells exploit CD47 to block phagocytosis by APCs and dampen anti-tumor immune responses. Various inhibitors of the CD47-SIRPα signaling axis, including monoclonal antibodies, have been developed as immunotherapeutic agents for administering CD47 blocka

APA, Harvard, Vancouver, ISO, and other styles

34

Huang, Xiting, Qian Wang, Yanyang Nan, et al. "Targeting CD47 and Angiogenesis Demonstrates Effective Anti-Tumor Effect in Bladder Cancer." Biomedicines 12, no. 9 (2024): 2152. http://dx.doi.org/10.3390/biomedicines12092152.

Full text

Abstract:

Background: Although immunotherapy has shown potential in cancer treatment, current immunotherapeutics for bladder cancer are limited by a low response rate. Therefore, it is necessary to investigate other suitable immunotherapeutic targets and strategies for bladder cancer. Methods: To evaluate whether CD47 could be a suitable target for bladder cancer immunotherapy, CD47 protein expression levels in 116 bladder cancer tissue samples were assessed by IHC staining. In vitro anti-tumor effect of blocking CD47 was examined by phagocytosis assays. In vivo anti-tumor effects of targeting CD47 and

APA, Harvard, Vancouver, ISO, and other styles

35

Sammartano, Vincenzo, Elena Bestoso, Paola Pacelli, et al. "Prognostic Impact of CD47 Overexpression in Patients with Acute Myeloid Leukemia." Blood 144, Supplement 1 (2024): 6084. https://doi.org/10.1182/blood-2024-194696.

Full text

Abstract:

Background. CD47 is a membrane protein of the so-called “don't eat me signal” of innate immunity, capable of inhibiting phagocytosis by binding to the signal regulatory protein alpha (SIRPα) receptor on the surface of macrophages. Hematological malignancies express high levels of CD47 and interactions between the CD47 expressed on tumor cells and SIRPα of macrophages inhibit phagocytosis and determine immune evasion of neoplastic cells. High expression of CD47 in patients with acute myeloid leukemia (AML) has been associated with poor prognosis and disease relapse. Therapeutic approaches throu

APA, Harvard, Vancouver, ISO, and other styles

36

Bang, Seongsik, Seungyun Jee, Hwangkyu Son, et al. "CD47 Expression in Non-Melanoma Skin Cancers and Its Clinicopathological Implications." Diagnostics 12, no. 8 (2022): 1859. http://dx.doi.org/10.3390/diagnostics12081859.

Full text

Abstract:

CD47 is a cell surface molecule and regulates diverse cellular responses. CD47 is highly expressed in cancer cells and has potential as a therapeutic target and prognostic factor in cancer patients. The expression patterns of CD47 in basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and its precursor lesions, and its clinicopathological significance were investigated. CD47 expression was evaluated by immunohistochemistry in 152 cases of BCC and 71 cases of SCC. For comparison of CD47 expression, actinic keratosis (AK), squamous cell carcinoma in situ (SCCIS), keratoacanthoma (KA), and

APA, Harvard, Vancouver, ISO, and other styles

37

Zhang, Huimin, Haiquan Lu, Lisha Xiang, et al. "HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells." Proceedings of the National Academy of Sciences 112, no. 45 (2015): E6215—E6223. http://dx.doi.org/10.1073/pnas.1520032112.

Full text

Abstract:

Increased expression of CD47 has been reported to enable cancer cells to evade phagocytosis by macrophages and to promote the cancer stem cell phenotype, but the molecular mechanisms regulating CD47 expression have not been determined. Here we report that hypoxia-inducible factor 1 (HIF-1) directly activates transcription of the CD47 gene in hypoxic breast cancer cells. Knockdown of HIF activity or CD47 expression increased the phagocytosis of breast cancer cells by bone marrow-derived macrophages. CD47 expression was increased in mammosphere cultures, which are enriched for cancer stem cells,

APA, Harvard, Vancouver, ISO, and other styles

38

Yang, Jiaying, Yongjun Yao, Li Tong, Ziwei Zhu, Lei Wang, and Jinju Yang. "CD47 is highly expressed in gliomas and targeting CD47 is a promising therapeutic strategy." European Journal of Inflammation 19 (January 2021): 205873922110008. http://dx.doi.org/10.1177/20587392211000899.

Full text

Abstract:

Gliomas are very malignant brain tumors that are difficult to treat. CD47 is an antiphagocytic molecule that binds to SIPRα on phagocytes. It is overexpressed on the plasma membranes of multiple human tumor cell types and is an important diagnostic and prognostic biomarker in many types of cancer. However, the association between CD47 protein expression in glioma tissue and clinicopathological stage has not been investigated in detail. A total of 80 surgical glioma specimens were stained with anti-CD47 antibody to assess the relationship between CD47 protein expression and clinicopathological

APA, Harvard, Vancouver, ISO, and other styles

39

Avent, Neil D., Zoe E. Plummer, and David J. Head. "CD47 Glycoprotein Interacts with p4.1R and p55 in the Erythrocyte." Blood 108, no. 11 (2006): 1126. http://dx.doi.org/10.1182/blood.v108.11.1126.1126.

Full text

Abstract:

Abstract CD47 is a 47–50kDa membrane glycoprotein with 5 known isoforms. The role of CD47 within the erythrocyte membrane remains the subject of much research and debate though we recently provided evidence that CD47 may function as an inducer of eryptosis (Head et al, 2005). As both a cytoskeletal linked fraction and a smaller membrane diffuse fraction of CD47 exists, it is most likely that there are a number of protein species that are able to bind to CD47 at its cytoplasmic face. Our research has focused on a study of the molecular interactions of erythrocyte CD47 with erythrocyte membrane

APA, Harvard, Vancouver, ISO, and other styles

40

Dahl, Kris Noel, Connie M. Westhoff, and Dennis E. Discher. "Fractional attachment of CD47 (IAP) to the erythrocyte cytoskeleton and visual colocalization with Rh protein complexes." Blood 101, no. 3 (2003): 1194–99. http://dx.doi.org/10.1182/blood-2002-04-1187.

Full text

Abstract:

Abstract Interactions of CD47 and RhAG and the Rh proteins are visualized between one another and with the cytoskeleton of intact erythrocytes. In a first study, CD47 is labeled with a phycoerythrin (PhE)– tagged antibody, which generates discrete spots that reflect induced clusters of CD47. Rh and RhAG colocalize with each other and to these induced clusters, whereas Band 3 and glycophorin C remain more homogeneously dispersed on the cell periphery. In a second study, red cells are aspirated into a micropipette, and immunofluorescent maps of the surface gradients that develop for CD47 and RhA

APA, Harvard, Vancouver, ISO, and other styles

41

Lu, Zhiyuan. "Loss of cell surface CD47 ‘clustering’ formation and the binding avidity to SIRPα during epithelial cell apoptosis (IRC4P.453)". Journal of Immunology 194, № 1_Supplement (2015): 57.6. http://dx.doi.org/10.4049/jimmunol.194.supp.57.6.

Full text

Abstract:

Abstract CD47, a ‘self’ marker expressed in most cell types, interacts with immunoreceptor SIRPα expressed on phagocyte to initiate inhibitory signaling that prevents healthy cells from being cleared by phagocytes. Previous studies have suggested that cell may lose surface CD47 during cell aging or apoptosis. In the present study, we demonstrated that the majority of CD47 molecules localize in lipid rafts forming ‘punctate’ pattern in healthy cells, whereas in apoptotic cells, the level of cell surface CD47 wasn’t decreased, but CD47 moved out of rafts and redistributed evenly on the plasma me

APA, Harvard, Vancouver, ISO, and other styles

42

Zhao, Yunteng, Xiaoxiao Yu, Haocheng Tang, et al. "MicroRNA-200a Promotes Phagocytosis of Macrophages and Suppresses Cell Proliferation, Migration, and Invasion in Nasopharyngeal Carcinoma by Targeting CD47." BioMed Research International 2020 (February 21, 2020): 1–13. http://dx.doi.org/10.1155/2020/3723781.

Full text

Abstract:

Nasopharyngeal carcinoma (NPC) causes severe oncogenic lesions in the nasopharynx. CD47, a transmembrane integrin-associated protein, plays a key role in the ability of tumor cells to escape phagocytosis, working as an immune checkpoint in the immune response. Besides this role, CD47 has been reported to regulate cell proliferation and migration. The present study addresses the relationship between CD47 and microRNA-200a and examines their regulatory mechanisms in NPC. Bioinformatics analyses and dual-luciferase reporter assays were used to confirm the putative relationship between miR-200a an

APA, Harvard, Vancouver, ISO, and other styles

43

Catani, Lucia, Daria Sollazzo, Francesca Ricci, et al. "The CD47 Pathway Is Deregulated In Human Immune Thrombocytopenia (ITP)." Blood 116, no. 21 (2010): 3776. http://dx.doi.org/10.1182/blood.v116.21.3776.3776.

Full text

Abstract:

Abstract Abstract 3776 The CD47 antigen is a transmembrane glycoprotein ubiquitously expressed on hematopoietic and non-hematopoietic cells. It serves as a receptor for Thrombospondin (TSP) and a ligand for signal regulatory protein-alpha (SIRP-alpha) receptor, acting, respectively, as a regulator of apoptosis and as antagonistic to phagocyte activity. Ligation of CD47 with antibodies, its natural physiological ligand TSP or the specific CD47-binding peptide 41NK induces apoptosis in nucleated blood cells. This apoptosis is characterized by mitochondrial damage and the exposure of phosphatydil

APA, Harvard, Vancouver, ISO, and other styles

44

Kaur, Sukhbir, Kyle V. Cicalese, Rajdeep Banerjee, and David D. Roberts. "Preclinical and clinical development of therapeutic antibodies targeting functions of CD47 in the tumor microenvironment." Antibody Therapeutics 3, no. 3 (2020): 179–92. http://dx.doi.org/10.1093/abt/tbaa017.

Full text

Abstract:

ABSTRACT CD47 is a ubiquitously expressed cell surface glycoprotein that functions as a signaling receptor for thrombospondin-1 and as the counter-receptor for signal regulatory protein-α (SIRPα). Engaging SIRPα on macrophages inhibits phagocytosis, and CD47 thereby serves as a physiological marker of self. However, elevated CD47 expression on some cancer cells also protects tumors from innate immune surveillance and limits adaptive antitumor immunity via inhibitory SIRPα signaling in antigen-presenting cells. CD47 also mediates inhibitory thrombospondin-1 signaling in vascular cells, T cells,

APA, Harvard, Vancouver, ISO, and other styles

45

Isenberg, Jeff S., David D. Roberts, and William A. Frazier. "CD47." Arteriosclerosis, Thrombosis, and Vascular Biology 28, no. 4 (2008): 615–21. http://dx.doi.org/10.1161/atvbaha.107.158154.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Noblejas-López, María del Mar, Mariona Baliu-Piqué, Cristina Nieto-Jiménez, et al. "Transcriptomic Profiles of CD47 in Breast Tumors Predict Outcome and Are Associated with Immune Activation." International Journal of Molecular Sciences 22, no. 8 (2021): 3836. http://dx.doi.org/10.3390/ijms22083836.

Full text

Abstract:

Targeting the innate immune system has attracted attention with the development of anti- CD47 antibodies. Anti-CD47 antibodies block the inhibition of the phagocytic activity of macrophages caused by the up-regulation of CD47 on tumor cells. In this study, public genomic data was used to identify genes highly expressed in breast tumors with elevated CD47 expression and analyzed the association between the presence of tumor immune infiltrates and the expression of the selected genes. We found that 142 genes positively correlated with CD47, of which 83 predicted favorable and 32 detrimental rela

APA, Harvard, Vancouver, ISO, and other styles

47

Kaur, Sukhbir, Duha Awad, Richard P. Finney, et al. "CD47-Dependent Regulation of Immune Checkpoint Gene Expression and MYCN mRNA Splicing in Murine CD8 and Jurkat T Cells." International Journal of Molecular Sciences 24, no. 3 (2023): 2612. http://dx.doi.org/10.3390/ijms24032612.

Full text

Abstract:

Elevated expression of CD47 in some cancers is associated with poor survival related to its function as an innate immune checkpoint when expressed on tumor cells. In contrast, elevated CD47 expression in cutaneous melanomas is associated with improved survival. Previous studies implicated protective functions of CD47 expressed by immune cells in the melanoma tumor microenvironment. RNA sequencing analysis of responses induced by CD3 and CD28 engagement on wild type and CD47-deficient Jurkat T lymphoblast cells identified additional regulators of T cell function that were also CD47-dependent in

APA, Harvard, Vancouver, ISO, and other styles

48

Zhang, Hefeng, Shihu Liu, Jinzi Zhang, and Yongjie Wang. "CD47 expression in non-small cell lung cancer and its relationship with tumor-associated macrophage infiltration." PLOS ONE 19, no. 12 (2024): e0314228. https://doi.org/10.1371/journal.pone.0314228.

Full text

Abstract:

Background Non-small cell lung cancer (NSCLC) has a high incidence, with most patients diagnosed beyond the optimal surgical window. Improving survival rates is critical to reducing lung cancer mortality, and identifying immune checkpoints is vital for prognosis stratification. Objective To investigate the expression of CD47 in NSCLC and its relationship with tumor-associated macrophage infiltration. Methods A retrospective analysis was conducted on 50 NSCLC patients treated between January 2014 and June 2018. Immunohistochemistry and confocal microscopy assessed CD47 expression in tumor and a

APA, Harvard, Vancouver, ISO, and other styles

49

Huang, Kaisheng, Yi Liu, Shuixiu Wen та ін. "Binding Mechanism of CD47 with SIRPα Variants and Its Antibody: Elucidated by Molecular Dynamics Simulations". Molecules 28, № 12 (2023): 4610. http://dx.doi.org/10.3390/molecules28124610.

Full text

Abstract:

The intricate complex system of the differentiation 47 (CD47) and the signal-regulatory protein alpha (SIRPα) cluster is a crucial target for cancer immunotherapy. Although the conformational state of the CD47-SIRPα complex has been revealed through crystallographic studies, further characterization is needed to fully understand the binding mechanism and to identify the hot spot residues involved. In this study, molecular dynamics (MD) simulations were carried out for the complexes of CD47 with two SIRPα variants (SIRPαv1, SIRPαv2) and the commercially available anti-CD47 monoclonal antibody (

APA, Harvard, Vancouver, ISO, and other styles

50

Jagasia, Sarisha, Andra Krauze, Yingdong Zhao, et al. "SDPS-29 SERUM-DERIVED CD47 AS A MARKER OF TUMOR BURDENAND OUTCOME IN GBM PATIENTS – CORRELATIVE ANALYSISOF TUMOR LOCATION, RADIATION THERAPY VOLUMES,AND SURVIVAL." Neuro-Oncology Advances 5, Supplement_3 (2023): iii22. http://dx.doi.org/10.1093/noajnl/vdad070.084.

Full text

Abstract:

Abstract Glioblastomas (GBM) are the most aggressive central nervous system tumors exhibiting near universal recurrence following resection and chemoradiation (CRT). CD47 is an integrin-associated transmembrane protein associated with immunomodulation, invasion, and stemness that is highly expressed in GBM. We tested the hypothesis patient serum-derived CD47 measured pre vs. post-CRT may be related to tumor burden by exploring its association with tumor dissemination in the brain, RT volumes, and outcomes. CD47 was analyzed using an aptamer-based SOMAscan proteomic assay on serum collected pre

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!